 SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 GLOBE NEWSWIRE Pliant Therapeutics, Inc. Nasdaq: PLRX, a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underwritten public offering of 8,333,334 shares of its common stock at a price to the public of 30.00 ... The post Pliant Therapeutics Announces Pricing of Upsized 250.0 Million Public Offering appeared first on ForexTV... 